ASX Health Stocks: Hydrix implants world’s first Guardian heart attack alert system
Health & Biotech
Health & Biotech
Link copied to
The biggest winner in health stocks today was Hydrix (ASX:HYD) – up 9.68% off the back of news that Angel Medical Systems had completed its first commercial implantation in the US of the Guardian device – a cardiac detection monitor and patient warning system.
The implant marks the first use of the Guardian following its recent FDA approval, and cardiac electrophysiologist and cardiologist Dr Andrew Kaplan – who performed the procedure – said it marks a “pivotal advancement in cardiac care”.
“Given the device’s clinical success, the cardiovascular community can feel confident in this new, first-in-kind technology,” he said.
Hydrix recently announced it had completed its application to the Australian Therapeutic Goods Administration (TGA) for the Guardian System’s inclusion on the Australian Register of Therapeutic Goods (ARTG).
Approval could be as soon as the first half of CY2022, after which the company will be able to market and sell the system commercially in Australia.
“[The procedure] reinforces our confidence in achieving our goals as we progress towards commercialisation of the world’s only implantable heart attack alert system,” Hydrix general manager Paul Kelly said.
Up 6.12% was Suda Pharma after announcing the appointment of senior cell and gene therapy manufacturing expert Dr Sandhya Buchanan as VP of manufacturing and quality for the company’s newly acquired iNKT cell therapy platform.
Dr Buchanan’s role will encompass leading the technology transfer, manufacturing, and quality aspects for production of the cell therapy for clinical development stages.
Bionomics Limited (ASX:BNO) +3.33%
The clinical stage biopharma company was up 3.33% after announcing plans to conduct a US initial public offering (IPO).
The proposed offering is expected to commence after the US Securities and Exchange Commission completes its review process of a registration statement relating to the proposed offering.
Lumos Diagnostics (ASX:LDX) +2.21%
Momentum is building for the rapid point-of-care (POC) diagnostic company following its ASX listing in early July.
Lumos was up 2.21% after releasing its unaudited financial results for FY21 which suggest the company is on track to exceed its prospectus revenue forecast of $23.7 million by around 5%.
Plus, the company’s client has secured US FDA Emergency Use Authorization (EUA) for a rapid, oral COVID-19 antibody test which it manufactures.
Orthocell (ASX:OCC) +1.87%
Orthocell rose 1.87% today after the publication of a breakthrough tissue engineering study combining CelGro with lymphatic and blood vessel cells to create functional lymphatic tissue.
The findings represent a substantial advance in the ex vivo fabrication of implantable lymphatic grafts and their use in novel surgical treatments for patients suffering from Lymphedema.
The study essentially further validates CelGro as the ideal collagen scaffold that can be used on its own or in combination with cells to fabricate complex tissue grafts to replace damaged tissue or augment repair of defects.
And down 5.7% was Anteris Technologies after news of a planned $9 million capital raising to fund working capital for the development of DurAVRTM, the company’s 3D single-piece aortic valve for the treatment of aortic stenosis.